超越HNA-1：抗hna -3自身抗体在自身免疫性中性粒细胞减少症中的作用。

IF 2.8 4区医学 Q3 IMMUNOLOGY

Immunology letters Pub Date : 2025-09-25 DOI:10.1016/j.imlet.2025.107095

Renato Cerqueira, Elyse Moritz, Josefina A P Braga, Akemi K Chiba, João B Pesquero, José O Bordin

{"title":"超越HNA-1：抗hna -3自身抗体在自身免疫性中性粒细胞减少症中的作用。","authors":"Renato Cerqueira, Elyse Moritz, Josefina A P Braga, Akemi K Chiba, João B Pesquero, José O Bordin","doi":"10.1016/j.imlet.2025.107095","DOIUrl":null,"url":null,"abstract":"Introduction: Autoimmune neutropenia (AIN), a common cause of chronic neutropenia, has been categorized as primary (pAIN) and secondary (sAIN). This study investigates the specificity of anti-HNA autoantibodies in both types.Materials and methods: A prospective cohort study of 85 chronic neutropenia patients included those with detectable anti-HNA autoantibodies. Anti-HNA was assessed using granulocyte agglutination (GAT), granulocyte immunofluorescence (GIFT), and LABScreen Multi Kit (LSM). Molecular analysis was performed to assess HNA expression.Results: Of 85 patients, 7 had pAIN and 8 had sAIN. All pAIN patients exhibited only anti-HNA-1, while anti-HNA-3 was found in 3/8 sAIN patients. All patients with anti-HNA-3 tested positive in LSM; one was positive in both GAT and GIFT.Discussion: While anti-HNA-3 has been described exclusively as an alloantibody, this is the first report of anti-HNA-3 as an autoantibody in AIN.Conclusion: Anti-HNA-3 autoantibody is associated only with sAIN, suggesting distinct mechanisms in pAIN and sAIN.","PeriodicalId":13413,"journal":{"name":"Immunology letters","volume":" ","pages":"107095"},"PeriodicalIF":2.8000,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Beyond HNA-1: The Anti-HNA-3 Autoantibody as a Protagonist in Autoimmune Neutropenia.\",\"authors\":\"Renato Cerqueira, Elyse Moritz, Josefina A P Braga, Akemi K Chiba, João B Pesquero, José O Bordin\",\"doi\":\"10.1016/j.imlet.2025.107095\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction: Autoimmune neutropenia (AIN), a common cause of chronic neutropenia, has been categorized as primary (pAIN) and secondary (sAIN). This study investigates the specificity of anti-HNA autoantibodies in both types.Materials and methods: A prospective cohort study of 85 chronic neutropenia patients included those with detectable anti-HNA autoantibodies. Anti-HNA was assessed using granulocyte agglutination (GAT), granulocyte immunofluorescence (GIFT), and LABScreen Multi Kit (LSM). Molecular analysis was performed to assess HNA expression.Results: Of 85 patients, 7 had pAIN and 8 had sAIN. All pAIN patients exhibited only anti-HNA-1, while anti-HNA-3 was found in 3/8 sAIN patients. All patients with anti-HNA-3 tested positive in LSM; one was positive in both GAT and GIFT.Discussion: While anti-HNA-3 has been described exclusively as an alloantibody, this is the first report of anti-HNA-3 as an autoantibody in AIN.Conclusion: Anti-HNA-3 autoantibody is associated only with sAIN, suggesting distinct mechanisms in pAIN and sAIN.\",\"PeriodicalId\":13413,\"journal\":{\"name\":\"Immunology letters\",\"volume\":\" \",\"pages\":\"107095\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-09-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Immunology letters\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.imlet.2025.107095\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunology letters","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.imlet.2025.107095","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

自身免疫性中性粒细胞减少症（AIN）是慢性中性粒细胞减少症的常见原因，可分为原发性（pAIN）和继发性（sAIN）。本研究探讨了两种类型的抗海航自身抗体的特异性。材料和方法：对85例慢性中性粒细胞减少患者进行前瞻性队列研究，其中包括可检测到的抗海航自身抗体。采用粒细胞凝集（GAT）、粒细胞免疫荧光（GIFT）和LABScreen Multi Kit （LSM）检测抗海航抗体。通过分子分析评估海航蛋白的表达。结果：85例患者中，pAIN 7例，sAIN 8例。所有pAIN患者均有抗hna -1，而3/8的sAIN患者有抗hna -3。LSM患者抗hna -3阳性；1例GAT和GIFT均阳性。讨论：虽然抗hna -3被描述为一种专门的同种异体抗体，但这是AIN中首次报道的抗hna -3作为自身抗体。结论：抗hna -3自身抗体仅与sAIN相关，提示在pAIN和sAIN中存在不同的机制。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Beyond HNA-1: The Anti-HNA-3 Autoantibody as a Protagonist in Autoimmune Neutropenia.

Introduction: Autoimmune neutropenia (AIN), a common cause of chronic neutropenia, has been categorized as primary (pAIN) and secondary (sAIN). This study investigates the specificity of anti-HNA autoantibodies in both types.

Materials and methods: A prospective cohort study of 85 chronic neutropenia patients included those with detectable anti-HNA autoantibodies. Anti-HNA was assessed using granulocyte agglutination (GAT), granulocyte immunofluorescence (GIFT), and LABScreen Multi Kit (LSM). Molecular analysis was performed to assess HNA expression.

Results: Of 85 patients, 7 had pAIN and 8 had sAIN. All pAIN patients exhibited only anti-HNA-1, while anti-HNA-3 was found in 3/8 sAIN patients. All patients with anti-HNA-3 tested positive in LSM; one was positive in both GAT and GIFT.

Discussion: While anti-HNA-3 has been described exclusively as an alloantibody, this is the first report of anti-HNA-3 as an autoantibody in AIN.

Conclusion: Anti-HNA-3 autoantibody is associated only with sAIN, suggesting distinct mechanisms in pAIN and sAIN.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Immunology letters 医学-免疫学

CiteScore

7.60

自引率

0.00%

发文量

审稿时长

44 days

期刊介绍： Immunology Letters provides a vehicle for the speedy publication of experimental papers, (mini)Reviews and Letters to the Editor addressing all aspects of molecular and cellular immunology. The essential criteria for publication will be clarity, experimental soundness and novelty. Results contradictory to current accepted thinking or ideas divergent from actual dogmas will be considered for publication provided that they are based on solid experimental findings. Preference will be given to papers of immediate importance to other investigators, either by their experimental data, new ideas or new methodology. Scientific correspondence to the Editor-in-Chief related to the published papers may also be accepted provided that they are short and scientifically relevant to the papers mentioned, in order to provide a continuing forum for discussion.